Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05919264 · ClinicalTrials.gov registry record · Phase 1
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Cancer and Colorectal Cancer, sponsored by Parabilis Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 575
- Enrollment target
- 20
- Study locations
NCT05919264: Recruiting Phase 1 study of Cancer and Colorectal Cancer, sponsored by Parabilis Medicines.
NCT05919264 is a Phase 1 study of Cancer and Colorectal Cancer that is actively recruiting participants, run by Parabilis Medicines. The registered enrollment target is 575 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05919264, a Phase 1 study of Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Parabilis Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 575 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
Primary Outcome
Number and severity of treatment emergent adverse events as assessed by CTCAE v5.0
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Nivolumab
- DRUG FOG-001
- DRUG mFOLFOX-6
- DRUG Trifluridine/tipiracil
Study Locations (20)
California
- Stanford Cancer Institute, Stanford University - Palo Alto
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center - San Francisco
- Sarcoma Oncology Center - Santa Monica
Arizona
- Honor Health - Scottsdale
- Arizona Cancer Center at University of Arizona - Tucson
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Ohio
- University Hospitals Cleveland Medical Center, Seidman Cancer Center - Cleveland
- Cleveland Clinic - Cleveland
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- Johns Hopkins University, Sibley Memorial Hospital - Washington D.C.
Florida
- Florida Cancer Specialists - Lake Mary
Maryland
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 575 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
What NCT05919264 shows while recruiting
NCT05919264 is an interventional study that assigns participants to a tested intervention. The registered 575 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (84% lower).
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT05919264 names 20 study sites across 15 states, led by California, Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05919264 about?
NCT05919264 is a clinical study titled "FOG-001 in Locally Advanced or Metastatic Solid Tumors". The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
What is the current status of trial NCT05919264?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 575 participants. The study started on 2023-05-23. Estimated completion is 2027-08-31.
What conditions does trial NCT05919264 study?
This clinical trial studies the following conditions: Cancer, Colorectal Cancer, Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor.
What interventions are being tested in trial NCT05919264?
The interventions under investigation include: Bevacizumab (DRUG), Nivolumab (DRUG), FOG-001 (DRUG), mFOLFOX-6 (DRUG), Trifluridine/tipiracil (DRUG).
Who is sponsoring clinical trial NCT05919264?
This trial is sponsored by Parabilis Medicines, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05919264 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05919264's enrollment target sits among peer trials
575 114th of 615 higher than 502 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
- NCT06583148 · 575 participants · NA
A Smoke-Free Home Intervention in Tribal Communities
- NCT06883175 · 575 participants · NA
Evolution of the Chicago Classification: Bridging Physiology and Mechanics
- NCT04931810 · 576 participants · NA
Urban and Reservation Implementation of All Nations Breath of Life
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI